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6KRUWUXQQLQJWLWOH³Certolizumab pegol for treating RA following inadequate response to a TNFi: An 
ERG perspective´ 
Abstract 
As part of its single technology appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer (UCB Pharma) of certolizumab pegol (CZP;Cimzia®) to 
submit evidence of its clinical and cost-effectiveness for the treatment of rheumatoid arthritis (RA) 
following inadequate response to a tumour necrosis factor-alpha inhibitor (TNFi). The School of 
Health and Related Research Technology Appraisal Group at the University of Sheffield was 
commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a 
detailed review of the evidence for the clinical and cost-effectiveness of the technology, based upon 
WKHFRPSDQ\¶VVXEPLVVLRQWR1,&( The clinical effectiveness evidence in the FRPSDQ\¶VVXEPLVVLon 
for CZP was based predominantly on six randomised controlled trials (RCTs) comparing the efficacy 
of CZP against placebo. The clinical-effectiveness review identified no head to head evidence on the 
efficacy of CZP against the comparators within the scope; therefore the company performed a 
network meta-analysis (NMA). 7KHFRPSDQ\¶V10$FRQFOXGHG WKDWCZP had a similar efficacy to 
that of its comparators. The company submitted a Markov model that assessed the incremental cost 
effectiveness of CZP versus comparator biologic disease-modifying antirheumatic drugs (bDMARDs) 
for the treatment of RA from the perspective of the National Health Service for three decision 
problems each of which followed an inadequate response to a TNFi. These were (i) a comparison 
against rituximab (RTX) in combination with methotrexate (MTX); (ii) a comparison against 
bDMARDs when RTX was contraindicated or withdrawn due to an adverse event; and (iii) a 
comparison against bDMARDs when MTX was contraindicated or withdrawn due to an adverse 
event. 5HVXOWVIURPWKHFRPSDQ\¶VHFRQRPLFHYDOXDWLRQVKRZHGWKDW CZP resulted in similar number 
of QALYs produced at similar, or lower, costs as comparator bDMARDs. The commercial-in-
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confidence patient access schemes for abatacept and tocilizumab could not be incorporated by the 
company, but were incorporated by the ERG in a confidential appendix for the NICE Appraisal 
Committee (AC). The company estimated that the addition of CZP before RTX in a sequence for 
patients who could receive MTX, produced more quality-adjusted life years (QALYs) at an increased 
cost, with a cost per QALY of £33,222. Following a critique of the model, the ERG undertook 
exploratory analyses that did not change the conclusions reached based on the FRPSDQ\¶VHFRQRPLF
evaluation in relation to the comparison with bDMARDs. The ERG estimated that where CZP 
replaced RTX, CZP was dominated, as it produced less QALYs at an increased cost. The AC 
concluded that there was little difference in effectiveness between CZP and comparator bDMARDs 
and that equivalence among bDMARDs could be accepted. The AC consequently recommended CZP 
plus MTX for people for whom RTX is contraindicated or not tolerated and CZP monotherapy for 
people for whom MTX is contraindicated or not tolerated. The AC concluded that CZP plus MTX 
could not be considered a cost-effective use of National Health Service resources when RTX plus 
MTX is a treatment option.   
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Key points for decision makers 
x Certolizumab pegol (CZP) has shown similar clinical efficacy to other recommended biologic 
disease-modifying antirheumatic drugs (bDMARDs) in patients who had an inadequate 
response to tumour necrosis factor-alpha inhibitors (TNFi). The lack of published evidence on 
the effectiveness of some comparators following inadequate response to a TNFi adds 
considerable uncertainty to the incremental cost-effectiveness of CZP. 
 
x In the population eligible for rituximab (RTX) in combination with methotrexate (MTX), 
RTX is of similar clinical efficacy to CZP but has a significantly lower cost. Therefore, RTX 
in combination with MTX should be preferred to CZP with MTX. 
 
x In the population for whom RTX is contraindicated or withdrawn, CZP in combination with 
MTX has a similar efficacy and comparable costs to other bDMARDs in combination with 
MTX recommended by the National Institute for Health and Care Excellence (NICE). 
 
x In the population for whom MTX is contraindicated or withdrawn, CZP monotherapy has a 
similar efficacy and comparable cost to some of the other bDMARD monotherapies 
recommended by NICE. 
 
x The relative simplicity of the decision when bDMARDs were the main comparator provides 
supportive evidence that abbreviated appraisals which have been proposed by NICE where 
efficacy and costs are comparable can be delivered. 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after 
their UK market authorisation.[1] Within the STA process, the company provides NICE with a 
ZULWWHQVXEPLVVLRQDORQJVLGHDPDWKHPDWLFDOPRGHOWKDWVXPPDULVHVWKHFRPSDQ\¶VHVWLPDWHVRIWKH
clinical and cost effectiveness of the technology. This submission is reviewed by an external 
organisation independent of NICE (the Evidence Review Group [ERG]), which consults with clinical 
specialists and produces a report. After consideration of the compDQ\¶VVXEPLVVLRQ WKH(5*UHSRUW
and testimony from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates 
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preliminary guidance, the Appraisal Consultation Document (ACD), which indicates the initial 
decision of the AC regarding the recommendation (or not) of the technology. Stakeholders are then 
invited to comment on the submitted evidence and the ACD, after which a further ACD may be 
produced or a Final Appraisal Determination (FAD) issued, which is open to appeal. An ACD is not 
produced when the technology is recommended within its full marketing authorisation; in this case, a 
FAD is produced directly. 
 
This paper presents a summary of the ERG report[2] for the STA of certolizumab pegol (CZP) for 
treating rheumatoid arthritis (RA) following inadequate response to a tumour necrosis factor-alpha 
inhibitor (TNFi) and a summary of the subsequent development of the NICE guidance for the use of 
this technology in England. Full details of all relevant appraisal documents (including the appraisal 
scope, ERG report, company and consultee submissions, FAD and comments from consultees) can be 
found on the NICE website.[3] 
 
2. The Decision Problem 
RA is a chronic inflammatory disease characterised by progressive, irreversible joint damage, 
impaired joint function, pain and tenderness caused by swelling of the synovial lining of joints and is 
manifested with increasing disability and reduced quality of life.[4] The primary symptoms are pain, 
morning stiffness, swelling, tenderness, loss of movement, fatigue, and redness of the peripheral 
joints.[5, 6] RA is associated with substantial costs both directly (due to drug acquisition and 
hospitalisation) and indirectly (due to reduced productivity).[7] RA has long been reported as being 
associated with increased mortality,[8, 9] particularly due to cardiovascular events.[10] There are an 
estimated 580,000 people in England and Wales with RA, with approximately 26,000 incident cases 
per year.[11] RA is more prevalent in females (1.16%) than in males (0.44%),[12] with the majority 
of cases being diagnosed between the ages of 40 and 80 years.[13]  
Two classifications have dominated the measurement of improvement in RA symptoms: American 
College of Rheumatology (ACR) responses[14] and European League Against Rheumatism (EULAR) 
responses.[15] ACR response has been widely adopted in randomised controlled trials (RCTs) 
although studies have shown that the value of the measure can vary between studies due to the timing 
of the response.[16]  In the UK, monitoring the progression of RA is often undertaken using the 
disease activity score of 28 joints (DAS28). The DAS28 can be used to classify both the disease 
activity of the patient and the level of improvement estimated within the patient. The EULAR 
response criteria use the individual change in DAS28 and the absolute DAS28 score to classify a 
EULAR response as good, moderate or none.[15] EULAR response has been reported less frequently 
in RCTs than ACR responses.[2] However, EULAR response is much more closely aligned to the 
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treatment continuation rules stipulated by NICE, which require either a moderate or good EULAR 
response or a DAS28 improvement of more than 1.2 points to continue treatment with biologic 
disease-modifying antirheumatic drugs (bDMARDs).  
 
2.1 Current Treatment 
For people with newly diagnosed RA, NICE recommends considering a combination of conventional 
disease-modifying antirheumatic drugs (cDMARDs), including methotrexate (MTX) and at least one 
other cDMARD plus short-term glucocorticoids, as first-line treatment, ideally beginning within 3 
months of the onset of persistent symptoms.[17]  NICE guidance (Technology Appraisal (TA) 
375)[18] recommends the use of the following bDMARDs: abatacept (ABA); adalimumab (ADA); 
CZP; etanercept (ETA); golimumab (GOL); infliximab (IFX); and tocilizumab (TOC) each in 
combination with MTX for patients who have severe active RA (defined as a DAS28 score greater 
than 5.1) after the failure to respond to cDMARD treatment. For people who meet these criteria but 
for whom MTX is contraindicated or has been withdrawn, NICE recommends the use of ADA, CZP, 
ETA and tocilizumab as monotherapy.[18] Most of these bDMARDs (all except ABA and TOC) are 
TNFis. After the failure of the first TNFi, NICE recommends rituximab (RTX) in combination with 
MTX for the treatment of severe active RA.[19] If RTX is contraindicated or withdrawn because of an 
adverse event (AE), NICE recommends ABA, ADA, ETA, GOL, IFX or TOC in combination with 
MTX [19-21]. If MTX is contraindicated or withdrawn because of an AE, NICE recommends ADA or 
ETA [19] as monotherapy. NICE also recommends TOC in combination with MTX as a third line 
biologic after inadequate response to RTX in combination with MTX.[20] 
Treatment continuation criteria vary across TAs: TA375[18] states that for patients to continue 
treatment with their first bDMARD treatment they must achieve and maintain at least a moderate 
EULAR response. For RTX, TA195[22]  states that treatment should be continued only if there is an 
improvement in the DAS28 score of at least 1.2 points at initiation of treatment and whilst this 
response is maintained. If the relevant continuation criterion is not met, then the treatment should be 
stopped and the next treatment in the sequence initiated.  
3. The Independent ERG Review 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
RQVSHFLILFSRLQWVLQWKHFRPSDQ\¶VVXEPLVVLRQ (CS),[23] in response to which the company provided 
additionaOLQIRUPDWLRQ7KH(5*DOVRPRGLILHGWKHFRPSDQ\¶VGHFLVLRQDQDO\WLFPRGHOWRSURGXFHDQ
ERG base case and to assess the impact of alternative parameter values and assumptions on the model 
UHVXOWV7KHHYLGHQFHSUHVHQWHGLQWKHFRPSDQ\¶VVXEPLVVLRQDQGWKH (5*¶VUHYLHZRIWhat evidence 
is summarised here. 
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3.1 Clinical Evidence Provided by the Company 
Evidence was presented in the CS[23] for the efficacy of CZP in combination with MTX and other 
cDMARDs or as monotherapy in the treatment of moderate to severe RA in patients with a previously 
inadequate response or intolerance to TNFi therapy. This evidence was based on six RCTs 
(REALISTIC,[24] DOSEFLEX,[25] PREDICT,[26] SWITCH,[27] J-RAPID[28] and HIKARI[29]). 
All of these trials recruited both TNFi-naïve and TNFi-experienced patients, with the exception of the 
SWITCH study, which was performed solely in a TNFi-experienced population. Five RCTs were 
placebo-controlled (PREDICT did not have a non-CZP comparator arm). The durations of the 
randomised controlled phases in the RCTs were: 12 weeks (REALISTIC and SWITCH); 16 weeks 
(DOSEFLEX); 24 weeks (J-RAPID and HIKARI); and 52 weeks (PREDICT). The primary outcome 
in four of the RCTs (REALISTIC, SWITCH, J-RAPID and HIKARI) was ACR20 response at week 
12. The primary endpoint of DOSEFLEX was ACR20 response at 34 weeks in patients randomised at 
week 18, whilst the primary endpoints in PREDICT were clinical disease activity scale (CDAI) and 
RAPID-3 scores at 12 and 52 weeks. J-RAPID and HIKARI were undertaken exclusively in Japan. 
The company also included supplementary observational evidence from the Swedish registry-based 
study ARTIS.[30]. Disease activity was reported in the CS[23] as ACR and EULAR responses, 
DAS28 and CDAI. The clinical effectiveness results of the described trials were confidential and 
therefore cannot be reported here. 
No head to head evidence evaluating CZP against comparator bDMARDs was available and therefore 
the company performed a Bayesian network meta-analysis (NMA) to assess the effectiveness of CZP 
compared with other recommended bDMARDs. The results of nine relevant RCTs were included in 
the NMA: three trials were included for CZP + MTX (REALISTIC,[24] J-RAPID[28] and 
SWITCH[27]); two for TOC + MTX (RADIATE,[31] Genovese et al., 2014[32]); two for RTX + 
MTX (REFLEX[33], Combe et al., 2012[34]); one for ETN + MTX (Combe et al., 2012[34]); one 
RCT for ABA + MTX (ATTAIN[35]); and, one for GOL + MTX (GO-AFTER[36]). The company 
only considered fixed effect models and justified its decision based on the limited number of studies. 
3.1.1 Critique of the Clinical Evidence and Interpretation 
The eligibility criteria applied in the selection of evidence for the clinical effectiveness review were 
considered by the ERG to be reasonable and generally consistent with the decision problem as 
outlined in the final NICE scope. The ERG was satisfied that the searches for clinical effectiveness 
evidence reported in the CS [23] were likely to have identified all relevant published RCT evidence.  
However, a RCT by Kang et al. (2012)[37] which included CZP was identified by the ERG and 
clarification was sought from the company as to why it was not included in the CS.[23] The company 
responded that the Kang et al. study was not included because the number of patients in the study who 
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were TNFi-experienced was small. However, the ERG noted that two CZP RCTs were included even 
if they also had low numbers of TNFi-experienced patients (J-RAPID and HIKARI) and therefore the 
ERG considered that the justification provided by the company to support their decision to exclude 
the Kang et al. study [37] was not applied consistently. 
The quality of the included RCTs including CZP and ARTIS non-randomised study were assessed 
using well established and recognised criteria. Data for radiological progression and joint damage 
were not presented in the CS,[23] however, data on inhibition of joint structural damage were 
available in the published articles for both J-RAPID and HIKARI. Extra-articular manifestations of 
disease were not included in the CS.[23] Study and patient characteristics for included CZP trials 
were clearly described in a narrative summary alongside clinical and safety data. However, p-values 
were frequently unreported and therefore the ERG requested that these be provided by the company 
where available. Classical meta-analyses were performed for CZP used in combination with MTX and 
for CZP as monotherapy. Classical meta-analyses were performed separately for the outcomes of 
ACR20/50/70; EULAR response; and DAS28 (Erythrocyte Sedimentation Rate (ESR)) remission at 3 
months. No meta-analysis was performed for outcomes at 6 months due to data unavailability. Both 
fixed effects (Mantel-Haenszel) and random effects (DerSimonian and Laird) models were used. 
Heterogeneity between trials was investigated using I2 values. The ERG noted that it is generally 
recommended that at least five studies should be available for a frequentist meta-analysis, whereas the 
analyses in the CS[23] included, at most, only three studies. A Bayesian NMA was performed to 
assess CZP against comparator interventions, which had several limitations. The ERG believed that 
several changes would have been required to the analyses conducted and to the reporting of the results 
in order for them to represent the genuine uncertainty and be useful for decision-making purposes. 
These changes included: incorporating weakly informative prior information for the between-study 
standard deviation; generating predictive distributions of the effects of treatments in a new study; 
using the evidence from the REALISTIC study to generate the probabilities of being in each ACR and 
EULAR category for the reference treatment; and taking draws from the joint posterior distribution of 
treatment effects rather than assuming univariate normal distributions for them. It was not possible for 
the ERG in the time available to make the required changes to produce robust results and therefore the 
ERG did not amend the NMA presented in the CS.[23] 
 
3.2 Cost-Effectiveness Evidence Provided by the Company 
The company supplied a de novo cohort Markov model constructed in Microsoft Excel©. The 
perspective was that of the NHS and a six-month cycle length and a time horizon of 45 years 
(assumed to be lifetime) was used. A discount rate of 3.5% per annum was used both for costs and for 
utilities. Patients entered the model after inadequate response to a TNFi and transitioned to one of 
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three health states depending on their EULAR response: none, moderate or good. Non-responders 
discontinued treatment after a cycle and transitioned to a state representing the first six months of the 
first follow-up treatment. Good and moderate EULAR responders remained in their states until 
treatment discontinuation, after which they transitioned to the state representing the first six months of 
the next treatment in the sequence. Patients achieving good or moderate EULAR response in follow-
up treatments transitioned to a state representing the rest of the duration of the treatment whereas non-
responders transitioned to the state representing the first six months of the next follow-up treatment in 
the sequence. During any cycle, patients could transition from any of the alive states to death.  
The company considered three different populations: population A, formed by patients eligible for 
RTX in combination with MTX (RTX + MTX); population B, formed by patients for whom RTX is 
contraindicated or withdrawn due to an adverse event; and population C, formed by patients for whom 
MTX is contraindicated or withdrawn due to an adverse event. For population A, the company 
compared a sequence that it believed to reflect currently recommended clinical practice (consisting of 
RTX + MTX, TOC + MTX, ABA + MTX, MTX + hydroxychloroquine + sulfasalazine, non-biologic 
treatment mixture and palliative care) with a sequence consisting of CZP in combination with MTX 
(CZP + MTX) inserted at the start of the comparator sequence. For population B, the company 
compared a sequence starting with a treatment of CZP + MTX with the sequences starting with 
treatments of ABA, ADA, GOL, ETA, IFX, and TOC each in combination with MTX. For population 
C, the company compared a sequence starting with a treatment of CZP monotherapy with sequences 
starting with treatments of ADA, ETA and TOC monotherapies.  
The company modelled treatment efficacy for the first treatment in the sequence differently from 
subsequent treatments. The NMA conducted by the company was used to estimate the probabilities of 
no, moderate and good EULAR responses of CZP and comparators when the interventions were used 
in combination with MTX. The probabilities of EULAR responses for CZP and comparators when 
used as monotherapy was estimated based on the relative efficacy compared with CZP + MTX.  
Changes in HAQ score for each of the EULAR response categories were estimated using a linear 
regression fitted to data from the REALISTIC trial. Changes in EQ-5D from baseline was conditional 
on EULAR response to the first therapy and were estimated through a series of linear regression 
analyses with patient-level data from the PREDICT study.[26] Treatment discontinuation rate for 
patients with a good or moderate EULAR response was modelled with a Weibull distribution based 
on the Assessment Group¶VDSSURDFK in NICE TA195,[19] but assuming instead that all bDMARDs 
had the same discontinuation rate. 
For subsequent treatments, both the probabilities of EULAR response and the changes in HAQ scores 
conditioned on response were estimated based on the RADIATE study,[31] which analysed the 
efficacy of TOC + MTX compared with placebo + MTX in patients who had failed to respond to one 
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or more TNFis. Treatment discontinuation rate following response was assumed to be constant and 
equal to that of the first treatment between the sixth month and a year. 
3DWLHQWV¶Xtilities were assumed to depend on the HAQ score in each cycle. Patients achieving good or 
moderate EULAR response experienced a decrease (improvement) in HAQ score, the value of which 
was added at treatment discontinuation. Whilst on bDMARD treatment the HAQ score was assumed 
to remain constant. Contrastingly, for patients on cDMARDs or palliative care the HAQ score was 
assumed to increase linearly at a rate of 0.045 and 0.06 per year respectively. Changes in EQ-5D were 
estimated following a linear mapping algorithm from changes in HAQ scores reported by Brennan et 
al.[38]. Mortality was assumed to be affected by HAQ score, with a hazard ratio of 1.43 per HAQ 
score point applied following Norton et al.[39] 
Unit costs were taken from the Personal Social Services Research Unit,[40] British National 
Formulary (BNF),[41] and NHS Reference Costs.[42] The cost of CZP and GOL used in the model 
included the public Patient Access Scheme (PAS) in place. For CZP, this results in the first ten 
syringes of CZP being provided to the NHS free of charge. The list prices reported in the BNF were 
used for the rest of the drugs, as directed by NICE.  Costs were valued in 2015 Great British pounds. 
In their base case analysis, the company estimated that for population A, the probabilistic incremental 
cost-effectiveness ratio (ICER) of adding CZP + MTX before the currently recommended treatment 
sequence was £33,222 per quality-adjusted life year (QALY) gained (0.290 QALYs gained at a cost 
of £9,842). For population B, the estimated probabilistic ICER of CZP + MTX versus GOL + MTX 
was £3,461 (0.256 QALYs gained at a cost of £884) whilst the estimated probabilistic ICER of TOC 
(intravenous (IV)) + MTX versus CZP + MTX was £132,783 (0.201 QALYs gained at a cost of 
£26,659). For population C, the estimated probabilistic ICER of CZP monotherapy versus ADA 
monotherapy was £3,461 (0.260 QALYs gained at a cost of £1,336) whilst the estimated probabilistic 
ICER of TOC (IV) monotherapy versus CZP monotherapy was £133,655 (0.196 QALYs gained at a 
cost of £26,179). One-way sensitivity analyses undertaken by the company, where the mean values 
were replaced with values from the relevant 95% confidence intervals, showed that the net monetary 
benefit of CZP, assuming a threshold of £30,000 per QALY gained was most sensitive to the 
efficacies of RTX + MTX, CZP (as monotherapy or in combination with MTX), and TOC (as 
monotherapy or in combination with MTX). Scenario analyses undertaken by the company showed 
that assuming the efficacy of CZP is equal to the other TNFis has the biggest impact on the ICER, 
followed by the treatment duration of RTX + MTX and assuming a flat HAQ score progression for 
cDMARDs and palliative care. All of these changes produced ICERs less favourable to CZP, with the 
exception of setting the efficacy of CZP equal to other bDMARDs in population C. 
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3.2.1 Critique of the Cost-Effectiveness Evidence and Interpretation 
The ERG had concerns regarding the NMAs used to estimate the efficacy of CZP and its comparators 
which was used to characterise uncertainty in the economic model. The company expected 
heterogeneity but assumed that a fixed effects model was appropriate. The evidence for the reference 
treatment from the REALISTIC study was assumed by the company to represent the evidence for the 
WDUJHW SRSXODWLRQ KRZHYHU WKH FRPSDQ\ RQO\ XVHG WKH ³QR EULAR UHVSRQVH´ UDWHV IURP WKH
REALISTIC study and used evidence from all other studies to estimate the response rates for other 
ACR and EULAR response categories. The company generated estimates of absolute probabilities of 
being in each ACR and EULAR response category using mean and standard deviations extracted from 
the NMA and assuming univariate normal. However, this approach fails to preserve the underlying 
joint distribution between parameters and using draws from the joint posterior distribution would have 
been preferred. The ERG also believed that the exclusion of J-RAPID from the NMA was not 
justified. 
The ERG noted that the company used a simplistic approach to map changes in HAQ score to changes 
in EQ-5D utility and that better approaches exist to capture the non-linearity of the relationship 
between HAQ score and EQ-5D.[43, 44] 
The ERG believed that the treatment sequences considered by the company for population A were 
inappropriate because they include TOC + MTX followed by ABA + MTX after RTX + MTX. 
Clinical experts consulted by the ERG claimed that usually TOC + MTX or ABA + MTX were 
provided, but not both.  
Due to the lack of published evidence of the efficacy of IFX, ADA and ETA, each in combination 
with MTX in patients with an inadequate response to a TNFi, the company assumed the efficacy of 
these drugs to be equal to that of GOL + MTX. Similarly, the company made assumptions on the 
efficacy of TOC, ADA and ETA, each used in monotherapy in patients with inadequate response to a 
TNFi due to the lack of published evidence. It was assumed that the relative efficacy of each 
intervention when used in combination with MTX compared with CZP + MTX was generalisable to 
when the treatment was used as a monotherapy. The ERG believes that these assumptions introduce 
considerable uncertainty which is not fully captured and that therefore the results of the base case 
analysis should be interpreted with caution. 
The company assumed the same treatment duration for all bDMARDs for its base case analysis, 
despite evidence suggesting different treatment durations for different bDMARDs.[19] The ERG 
notes that the company identified treatment duration as a parameter with a large impact on the ICER 
(especially in population A) in one of their scenario analyses. 
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The ERG had concerns regarding the modelling of the efficacy of subsequent treatments due to the 
lack of evidence on treatment efficacy in patients with an inadequate response to a previous TNFi. In 
addition, the ERG believed that the difference in the modelling of the first and subsequent treatments 
meant that the model was not properly suited to compare sequences of different lengths. 
3.3 Additional Work Undertaken by the ERG 
7KH(5*DSSOLHGD VHULHVRIPRGLILFDWLRQV WR WKHFRPSDQ\¶VEDVHFDVH DQDO\VLV7KHPRVW UHOHvant 
were: (i) adding biosimilars of IFX and ETA and subcutaneous (SC) formulations of TOC and ABA 
as comparators; (ii) comparing four possible sequences (CZP before RTX, CZP after RTX, no RTX, 
no CZP) for population A (iii) removing ABA + MTX treatment after TOC + MTX from the 
sequences in population A; (iv) using different durations for different treatments based on the data 
provided in TA195;[19] (v) setting the RTX retreatment interval to 7.35 months; (vi) using the results 
of the NMA including J-RAPID; (vi) amending the cost of TOC by considering the 80mg formulation 
DQG VHWWLQJ WKH PJ OLPLW SHU DGPLQLVWUDWLRQ UHFRPPHQGHG LQ 72&¶V VXPPDU\ RI Sroduct 
characteristics; and (vii) adjusting the mean HAQ improvements reported in RADIATE to be more 
appropriate for responders.  
These modifications resulted in the sequence including CZP + MTX being dominated in population A 
in WKH(5*¶VEDVHFDVHDQDO\Vis. For population B, the estimated probabilistic ICER of CZP + MTX 
versus GOL + MTX was £13,155 (0.287 QALYs gained at a cost of £3,774) whilst the estimated 
probabilistic ICER of TOC (SC) + MTX versus CZP + MTX was £43,994 (0.544 QALYs gained at a 
cost of £23,954). For population C, the estimated probabilistic ICER of CZP monotherapy versus 
ADA was £14,437 (0.291 QALYs gained at a cost of £4,206) whilst the estimated probabilistic ICER 
of TOC (SC) monotherapy versus CZP monotherapy was £45,090 (0.525 QALYs gained at a cost of 
£23,690). 
The ERG also undertook two scenario analyses: using the results from the NMA excluding J-RAPID, 
as the company did for its base case; and assuming ADA, ETA and IFX had the same efficacy as CZP 
(instead of assuming their efficacy was equal to that of GOL). The first scenario analysis had little 
impact on the results; contrastingly, the second scenario analysis showed very different results in 
which biosimilar ETA dominated CZP in populations B and C (population A was unaffected). 
However, there remained treatments currently recommended by NICE that were estimated to be less 
cost-effective than CZP. 
Estimates of the cost-effectiveness of CZP when the ABA and TOC PASs were taken into 
consideration were provided to the NICE AC in a confidential appendix. 
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3.4 Conclusions of the ERG Report 
7KH (5*¶V FULWLFDO DSSUDLVDO LGHQWLILHG D QXPEHU RI LVVXHV UHODWLQJ WR WKH FRPSDQ\¶V PRGHO DQG
analysis. The most pertinent of these relate to: (i) the weaknesses of the NMA; (ii) inclusion of two 
lines of bDMARDs after RTX + MTX; (iii) exclusion from the base case of biosimilars for IFX and 
ETA; (iv) exclusion from the base case of SC formulations of TOC and ABA; (v) assuming the same 
treatment duration for all bDMARDs; (vi) assuming a retreatment interval of RTX that was deemed 
too short by the NICE AC in TA195;[19] (vii) ignoring the 80 mg formulation of TOC and the 800mg 
limit per administration; and (viii) assuming that the mean HAQ improvements reported in RADIATE 
apply to responders. The ERG undertook a series RI H[SORUDWRU\ DQDO\VHV EDVHG RQ WKH FRPSDQ\¶V
submitted model in order to address the limitations listed above, however, no additional work was 
undertaken correcting the NMA and as such, the level of uncertainty in all presented results is 
underestimated. 
7KH(5*¶VEDVHFDVHanalysis suggests that for population A, CZP + MTX should not be used before 
57;  07; /LPLWDWLRQV RI WKH FRPSDQ\¶V PRGHO LQ WKH PHWKRGV IRU PRGHOOLQJ VXEVHTXHQW
treatments mean that the results of a fully incremental analysis comparing sequences of different 
lengths was deemed unreliable. However, when comparing sequences of equal length, the use of RTX 
+ MTX before CZP + MTX, or the use of RTX + MTX rather than CZP + MTX was dominant. This 
result is not unexpected given the similar efficacies of RTX + MTX and CZP + MTX and the lower 
acquisition price associated with RTX compared with CZP. 
For population B, the probabilistic ICER of CZP + MTX versus biosimilar ETA+ MTX is expected to 
be £12,116 per QALY gained and the probabilistic ICER of TOC(SC) + MTX versus CZP + MTX is 
expected to be £45,414 per QALY gained. These ICERs are less favourable to CZP + MTX than the 
FRPSDQ\¶VEDVHFDVH ,&(5V. However, the probability that CZP + MTX produces more net benefit 
than its comparators assuming a WTP threshold of £30,000 per QALY gained remains essentially 
unchanged at 0.96. However, the PAS for TOC has not been included in these calculations. 
For population C, the probabilistic ICER of CZP monotherapy versus biosimilar ETA monotherapy is 
estimated to be £13,784 per QALY gained and the probabilistic of TOC(SC) monotherapy versus 
CZP monotherapy is expected to be £46,501 per QALY gained. These ICERs are less favourable to 
CZP monotherapy than WKH FRPSDQ\¶V EDVH FDVH ,&(5V. However, the probability that CZP 
monotherapy produces more net benefit than its comparators assuming a WTP threshold of £30,000 
per QALY gained is reduced slightly to 0.96. However, the PAS for TOC has not been included in 
these calculations. 
Additional analyses undertaken by the ERG using this revised base case model indicate that excluding 
J-RAPID from the NMA has little impact on the results of the analyses. In contrast, assuming that 
ADA, IFX and ETA in combination with MTX have the same efficacy as CZP + MTX (rather than 
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GOL + MTX) leads to biosimilar ETA + MTX dominating CZP + MTX; similarly, assuming ADA 
and ETA monotherapy have the same efficacy as CZP monotherapy leads to biosimilar ETA 
monotherapy dominating CZP monotherapy. The ERG notes that even were CZP + MTX dominated 
by biosimilar ETA + MTX there remains comparators for which it is estimated that CZP + MTX is 
dominant, such as IFX + MTX and ADA + MTX. The latter two interventions will remain options for 
treatment in population B as they were recommended in TA195.  
With respect to WKH FRPSDQ\¶V HFRQRPLF DQDO\VLV DQG WKH (5*¶V DGGLWLRQDO H[SORUDWRU\ DQDO\VHV
there remain several potentially important areas of uncertainty: 
1. The lack of data on the efficacy of ETA, ADA and IFX in combination with MTX in patients 
who have not responded adequately to a TNFi; there is a similar lack of data on the efficacy 
of ETA and ADA monotherapy in these patients. Alternative assumptions for the efficacy of 
these drugs than used by the company produced markedly different results. This limitation 
had already been highlighted by the AC of TA195[19] and was acknowledged during the 
scoping meeting for the current appraisal. 
2. The scarcity of data on the efficacy of bDMARDs in general, and TNFis in particular, in 
patients who have had an inadequate response to two or more bDMARDs. There is also the 
possibility that there could be reduced efficacy of TNFis following inadequate response to a 
previous TNFi. 
3. The relative efficacies of the bDMARDs are uncertain given the limitations of the NMA 
within the CS,[23] namely: (i) not incorporating weakly informative prior information for the 
between-study standard deviation; not using predictive distributions of the effects of 
treatments in a new study; (ii) FDOFXODWLQJWKH³QRUHVSRQVH´UDWHVEDVHGRQO\RQ the evidence 
from the REALISTIC study and using the evidence from other sources only to estimate other 
response category rates instead of directly generating the probabilities of being in each 
response category; and, (iii) assuming univariate normal distributions treatment effects 
instead of taking draws from their joint posterior distribution.  
 
4. Key Methodological Issues 
7KH(5*FRQVLGHUHGWKDWWKHFRPSDQ\¶VPRGHOZDVQRWDSSURSULDWHWRFRPSDUHsequences of different 
lengths due to the difference in the implementation of the first and subsequent treatments and in the 
assumptions made when modelling subsequent treatments. Furthermore, the NMA used in the 
economic model had several shortcomings that prevented a genuine representation of uncertainty and 
limited its usefulness for decision-making purposes. Finally, the choice of a cohort model as 
modelling approach proved inappropriate to represent the nature of the disease. For example, the 
company acknowledged that due to the inability of cohort models to handle non-linear functions, they 
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had to use a linear HAQ progression for patients on cDMARDs or palliative care and their mapping of 
HAQ to EQ-5D was restricted to linear models. Additionally, the inability of cohort models to track 
the time a patient has spent in such treatments, resulted in the treatment discontinuation rate being 
assumed to be constant for subsequent treatments instead of time-dependent. An individual patient 
model would have resolved this methodological issue.  
The ERG noted that the conclusions of the FRPSDQ\¶V DQDO\VHV tally with the expectations before 
constructing a mathematical model, given the comparable efficacy and costs of the intervention and 
its comparators. The relative simplicity of this decision provides supportive evidence that abbreviated 
appraisals, which have been proposed by NICE,[45] can be delivered under conditions such as those 
in the CZP STA. 
5. National Institute for Health and Care Excellence Guidance  
In September 2016, on the basis of the evidence available (including verbal testimony of invited 
clinical experts and patient representatives), the AC produced guidance that CZP in combination with 
MTX was recommended as an option following an inadequate response to a TNFi for treating severe 
RA if RTX is contraindicated or not tolerated. The AC also produced guidance that CZP monotherapy 
was recommended if MTX was contraindicated or not tolerated. Both recommendations were 
conditional on the company providing CZP with the agreed PAS. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the Appraisal Committee. The full list of the 
issues considered by the AC can be found in the FAD.[46]  
 
5.1.1 Current Clinical Management 
The AC considered the current clinical management of severe active RA following inadequate 
response to a TNFi in England and noted that the NICE guidance recommends ADA, ETA, IFX, 
ABA, TOC and GOL (each with MTX) as options, when RTX (plus MTX) is contraindicated or not 
tolerated, and ADA and ETA monotherapy as alternative options if RTX therapy cannot be given 
because MTX is contraindicated or not tolerated. The AC heard from clinical experts that responses to 
bDMARDs differ between people and therefore it is important to have a range of options for 
bDMARD treatments. The AC was aware that the marketing authorisation covers the use of CZP in 
moderate to severe disease but that TA375[18]  recommends that treatment with a bDMARD should 
only be started when disease is severe, that is a disease activity (DAS28) score of more than 5.1. 
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5.1.2 Uncertainties in the Clinical evidence 
The AC FRQVLGHUHG WKHFRPSDQ\¶VFOLnical evidence and accepted that the results showed that CZP 
was more clinically effective than placebo. It understood that the only evidence available on the 
comparative effectiveness of CZP and the comparator bDMARDs ZDV IURP WKH FRPSDQ\¶V NMA. 
The committee concluded that there are uncertainties from the methods used and it could not reliably 
conclude whether CZP was more clinically effective than the comparator bDMARDs on the basis of 
the evidence presented by the company. The AC heard from the clinical experts that CZP, which is 
already in use in clinical practice, is not considered to be better or worse than other TNFi-s. The AC 
concluded that CZP has a similar efficacy to other available bDMARDs. 
 
5.1.3 Uncertainties in the Economic Modelling  
The AC had concerns about the company¶VDSSURDFKWRHYDOXDWLQJthe cost effectiveness of CZP plus 
MTX for patients for whom RTX plus MTX was an option. Specifically, the AC was not persuaded 
that a treatment sequence containing CZP and six other treatments should be compared with the same 
sequence without CZP. The AC was aware that using different sequence lengths can increase 
modelling uncertainties and concluded that treatment sequences of the same length are preferable. 
After consultation, the AC expressed uncertainties about the DVVXPSWLRQV XVHG LQ WKH FRPSDQ\¶V
model. The AC SUHIHUUHGWKH(5*¶VYDOXHVIRUWKH retreatment interval for RTX and using different 
treatment durations for TNFis and non-TNFi-s based on the REFLEX study and its extension. Based 
RQ WKH(5*¶VH[SORUDWRU\DQDO\VLV WKH$&FRQFOXGHG WKDWCZP plus MTX was not a cost-effective 
treatment in patients for whom RTX plus MTX was an option. 
For people for whom RTX or MTX are contraindicated or not tolerated, the AC noted the similarities 
in costs between bDMARDs and its conclusions on comparative efficacy, and therefore that 
equivalence among bDMARDs could be accepted. Therefore, the AC concluded that CZP plus MTX 
or CZP monotherapy can be considered a cost-effective use of NHS resources for people for whom 
RTX or MTX are contraindicated or not tolerated. 
6. Conclusions 
The evidence suggests that CZP plus MTX or as monotherapy has a similar efficacy for treating 
severe active RA following inadequate response to a TNFi to that of other bDMARDs already 
recommended by NICE. Therefore, CZP plus MTX or as monotherapy was considered by NICE to be 
a cost-effective use of NHS resources for people for whom RTX or MTX are contraindicated or not 
tolerated. However, the cost of RTX treatment is significantly lower than that of CZP with 
comparable efficacy so CZP was not considered by NICE to be a cost-effective use of NHS resources 
when RTX and MTX is a treatment option for a patient. 
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